A 2024 study found that d-amphetamine improved selected memory outcomes in aged male rats and restored a laboratory measure of norepinephrine release in brain tissue. The findings are experimental evidence in a particular animal model. They do not establish that amphetamine prevents dementia, reverses human brain aging, or improves every cognitive function.
What was tested—and in which animals?
Scognamiglio and colleagues studied young and aged male Fischer 344 rats using several experiments: neurotransmitter release from brain slices, novel-object recognition, a spatial-learning maze, and microscopic assessment of dendritic spines. These were different measurements in different experimental groups. Their observations should not be combined into a fictitious single large clinical trial.
The methods describe young rats aged 2–4 months and aged rats 18–22 months; portions of the results and figure legends describe aged animals as 18–24 months. Those source descriptions should be retained rather than converted into an exact human age equivalent.
The brain-slice experiment measured release, not a blood drug level
The investigators loaded cerebral cortical and hippocampal tissue with radiolabelled norepinephrine, then measured fractional release under specified stimulation conditions. Glutamate-stimulated release was lower in tissue from aged animals. Release produced by a depolarizing potassium stimulus was not comparably reduced.
Adding 1 micromolar d-amphetamine to the tissue preparation restored the reduced glutamate-stimulated release toward the level measured in untreated young tissue. This concentration refers to the experimental preparation. It is not a rat plasma concentration, a human therapeutic target, or a forensic blood threshold.
The contrast between glutamate and potassium stimulation matters. The experiment supports a more specific vulnerability in the tested signaling process than a claim that all neurotransmitter release had failed with aging.
Acute treatment improved one memory outcome in aged rats
For novel-object recognition, the acute experiment included 26 young and 29 aged rats. A single intraperitoneal dose of 0.5 mg/kg d-amphetamine was administered 20 minutes before the test phase, following a 24-hour interval after training. The outcome was preferential exploration of a novel versus familiar object.
Aged rats improved relative to their saline performance; young rats did not show a statistically significant acute improvement. That null finding is part of the result. The experiment does not support an unqualified claim that amphetamine enhanced recognition memory in every group.
In a further pharmacological test, low-dose propranolol pretreatment blocked the amphetamine-associated improvement. This supports involvement of beta-adrenergic signaling under the experimental conditions. It does not establish that norepinephrine is the only possible contributor to every amphetamine effect.
Chronic administration and persistence were separate questions
The chronic regimen used drinking water to target 0.25 mg/kg/day during the first week and 0.5 mg/kg/day during the second. Water consumption and body weight informed the estimated regimen; this differs from an individually injected dose.
Improved novel-object recognition remained evident two weeks after treatment stopped but was not maintained as a preference for the novel object at ten weeks. The young-group overall treatment analysis was nonsignificant, although some post-hoc comparisons were significant. Those distinctions argue against describing the benefit as uniform or permanent.
| Experiment | Unit and outcome | Interpretive boundary |
|---|---|---|
| Novel-object recognition | Individual rats; exploration preference | Not human everyday memory |
| Barnes maze | Four groups of 8, 10, 7 and 9 rats; latency and errors | Different cohort from recognition testing |
| Spine microscopy | 5–6 rats per group, with sampled dendritic segments | Segments are not independent animals |
What follows for human or forensic interpretation?
The maze and microscopy findings add converging preclinical observations, but neither measures human impairment, safe driving, or dementia prevention. The study used male animals from one strain, selected tasks, specific regimens and brain-tissue assays. A change in dendritic spine morphology is not a clinical diagnosis or proof of functional recovery in a person.
The defensible conclusion is that d-amphetamine altered particular biological and behavioral endpoints in this aged-rat model. Human efficacy, individualized dosing and clinical safety require separate evidence.
Primary scientific source
Scognamiglio S, Aljohani YM, Olson TT, Forcelli PA, Dezfuli G, Kellar KJ. Restoration of norepinephrine release, cognitive performance, and dendritic spines by amphetamine in aged rat brain. Aging Cell. 2024;23:e14087. doi:10.1111/acel.14087. Original commentary on the supplied animal and ex-vivo research; no source figures reproduced.
Leave a Reply